Denver is set to host the illustrious Psychedelic Science Conference in 2025, organized by the esteemed Multidisciplinary Association for Psychedelic Studies (MAPS). This grand event will take place at the Colorado Convention Center from June 16th to June 20th, 2025. Known for its rich history in hosting groundbreaking conferences, this will mark the fifth iteration…

The U.S. Food and Drug Administration (FDA) has recently accepted a groundbreaking New Drug Application (NDA) submitted by Lykos Therapeutics for MDMA-assisted therapy in the treatment of Post-Traumatic Stress Disorder (PTSD). This pivotal moment signifies a crucial step forward in the potential adoption of psychedelic-assisted treatments within conventional medical practices. Originating from the Multidisciplinary Association…

The Multidisciplinary Association for Psychedelic Studies (MAPS) reintroduces its Fiscal Sponsorship Program, signaling a new era of support for grassroots organizations within the psychedelic ecosystem. With over 10 years of impactful collaboration, MAPS has fostered nearly 70 mission-aligned groups globally, advancing the movement for psychedelic harm reduction, drug policy reform, and education. Fiscal sponsorship is a…

MAPS Public Benefit Corporation (“MAPS PBC”), a company dedicated to transforming mental healthcare, announced an oversubscribed Series A financing. MAPS PBC raised more than $100 million including conversion of previously issued convertible notes. The financing was led by Helena, a global problem-solving organization and investor, with participation from other mission-aligned and institutional investors, including, but not…